연구 및 보고서

Parkinson’s disease is a neurodegenerative disorder marked by dopamine neuron loss and Lewy bodies, causing motor and non‑motor symptoms; treatment includes dopamine therapy and deep brain stimulation.

Levodopa remains effective for motor symptoms of Parkinson’s disease, but long‑term use brings motor fluctuations and a range of non‑motor issues that heavily impact patients.

Preliminary research presented at the AAIC suggests former professional soccer players show greater brain atrophy and higher rates of depression and anxiety than the general population.

Dong-A ST disclosed nonclinical results for its Alzheimer’s drug candidates targeting ferroptosis (DA-7505) and tau aggregation (DA-7503) at the AAIC in London.

NCIA presented autophagy‑focused brain health research and unveiled the pharmacy‑only supplement NeuroAP at a Daegu pharmacist fair, with KAIST professor Park Ok‑nam discussing autophagy’s role in neurodegeneration.